| HOME >> BIOLOGY >> TECHNOLOGY |
SEATTLE, WA, Aug. 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) (the "Company") today announced the appointment of Diana Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. In this position, Dr. Hausman will be responsible for planning and implementing the clinical development program for the Company's pipeline of oncology product candidates.
"Dr. Hausman is an experienced oncologist who brings an extensive background in drug development to her new role at Oncothyreon," said Robert L. Kirkman, M.D, President and Chief Executive Officer. "Her leadership and knowledge of all aspects of cancer drug development will be very important as we prepare to move both PX-866, our inhibitor of PI-3 kinase, and PX-478, our inhibitor of hypoxia inducible factor 1-alpha, into Phase 2 trials. We are delighted to have her join our team."
"I am very pleased to join Oncothyreon at this particular time in the development of PX-866 and PX-478," said Dr. Hausman. "It is a unique opportunity to contribute to the registration strategy for two promising small molecule product candidates, each directed at an exciting target at the forefront of current cancer drug research."
Dr. Hausman joins Oncothyreon from Zymogenetics, Inc., Seattle, Washington, where she held a number of clinical research positions from 2005 to 2009, most recently as Senior Director of Clinical Research with responsibility for all therapeutic areas, including oncology, autoimmune disease and virology. Prior to Zymogenetics, Dr. Hausman led a global drug development team at Berlex Inc. in Seattle from 2002 until 2005. Dr. Hausman will assume her new role at Oncothyreon on September 1, 2009.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the tre
'/>"/>
| SOURCE Oncothyreon Inc. Copyright©2009 PR Newswire. All rights reserved |